Brazil Anvisa Approves EMS Generic Liraglutide Pens for Obesity, Diabetes

Brazil's Anvisa approved two generic liraglutide pens from EMS for obesity and type 2 diabetes, expanding access to GLP-1 treatments at lower cost. The generics, based on EMS's own Olire and Linux, are priced from R$ 84, potentially increasing competition in the weight-loss drug market. This follows the company's earlier launches and signals a shift toward affordable alternatives in Brazil.